GH earnings call summary

Prepared Highlights

• Q2 2025 total revenue grew 31% YoY to $232.1M, driven by oncology, biopharma, and screening (CFO).
• Oncology revenue grew 22% YoY to $158.7M; oncology volumes increased 30% YoY to ~64,000 tests, led by Guardant360 Liquid and Reveal (CFO).
• Guardant360 Liquid YoY volume growth accelerated for the fourth consecutive quarter, exceeding 20% in Q2 (CFO).
• Guardant360 Tissue ASP reached ~$2,000 in Q2, achieving the 2028 target three years ahead of schedule (CFO).
• Biopharma & data revenue hit a record $56M, up 28% YoY; two new companion diagnostic deals signed in Q2 (CFO).
• Shield screening revenue totaled $14.8M from ~16,000 tests; Shield non-GAAP gross margin improved to 48% in Q2 vs. 18% in Q1 2025 (CFO).
• Shield ASP was over $900 in Q2, up from ~$600 in Q1; Shield non-GAAP cost per test is now less than $500 (CFO).
• Non-GAAP gross margin was 66% in Q2, up from 60% in Q2 2024 (CFO).
• Adjusted EBITDA loss was $51.9M in Q2 2025, an improvement of $10M vs. Q2 2024 (CFO).
• Free cash flow burn was $65.9M in Q2 2025 vs. $99.1M in Q2 2024; cash balance ~$735M (CFO).

Official Guidance (Full Year 2025)

• Total revenue: $915M–$925M (growth ~24%–25% YoY), raised from $880M–$890M (CFO).
• Oncology revenue growth: ~20% YoY (prior: 18%); total oncology volume growth: >27% (prior: >25%) (CFO).
• Biopharma & data revenue growth: mid-teens (prior: low double-digit) (CFO).
• Shield revenue: $55M–$60M (prior: $40M–$45M); Shield test volume: 68,000–73,000 (prior: 52,000–58,000) (CFO).
• Non-GAAP gross margin: 63%–64% (prior: 62%–63%) (CFO).
• Non-GAAP operating expenses: $840M–$850M (11%–12% increase vs. 2024) (CFO).
• Free cash flow burn: $225M–$235M (improvement vs. $275M in 2024); screening-related burn ~$200M; remainder of business expected to reach FCF breakeven in Q4 2025 (CFO).

Mgmt Quotes

• "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines." (CEO)
• "We delivered a record quarter for our biopharma business, achieving all-time highs in both volume and revenue." (CEO)
• "We are extremely pleased to report that we are making great progress with Shield non-GAAP gross margin, which increased to 48% in Q2 compared to 18% in Q1 2025." (CFO)
• "We're increasing our full year 2025 revenue guidance for the second time this year to be in the range of $915 million to $925 million." (CFO)
• "We continue to expect our cash burn in 2025 to consist of approximately $200 million related to screening as we scale our Shield business and maximize our first-mover advantage." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — Mark Anthony Massaro

• Topic: G360 Liquid 增长驱动因素及 SERENA-6 影响
• Key points:
  • G360 在 Q2 实现了超过 20% 的增长。
  • SERENA-6 在 Q2 的影响极小，主要增长动力来自 Infinity Smart Liquid Biopsy 平台带来的产品市场契合度。
  • 管理层认为 CGP 液体活检市场仍处于早期阶段，未来有多年增长空间。
• Mgmt stance: 看多。核心产品增长强劲，且未来有药物获批带来的额外检测机会。

Q2 — Puneet Souda

• Topic: Shield 增长驱动、ASP 趋势及 Shield V2 进展
• Key points:
  • Shield 增长受市场需求、销售团队覆盖扩大及生产力提升驱动。
  • Shield ASP 从 Q1 的略高于 600 美元提升至 Q2 的超过 900 美元，主因是 ADLT 地位使 Medicare 费率从 920 美元升至 1495 美元，以及 Medicare Advantage 报销改善。
  • 预计下半年 ASP 约为 800 美元，略低于 Q2，因商业保险患者比例将随规模扩大而上升。
  • Shield V2 项目仍在积极推进中，但未提供数据更新时间表。
• Mgmt stance: 看多。Shield 商业表现强劲，ASP 显著提升，销售团队生产力超出预期。

Q3 — Daniel Gregory Brennan

• Topic: G360 增长来源及 Smart Liquid Biopsy 平台的市场接受度
• Key points:
  • G360 增长是广泛的，体现在每月订购的肿瘤科医生数量增加，以及单账户月均检测量提升。
  • 增长既来自液体活检利用率的整体市场扩大，也来自显著的市场份额获取。
  • Smart Liquid Biopsy 的性能特点（如亚型分析、免疫疗法/PARP 抑制剂适用性判断）在学术和社区肿瘤医生层面均引起共鸣。
• Mgmt stance: 看多。产品市场契合度远超竞品，且未来几个季度有更多新应用和功能将推出。

Q4 — Tycho W. Peterson

• Topic: Shield MCED 上市路径、诱导担忧及 USPSTF 风险
• Key points:
  • Shield MCED 已完成临床验证，Vanguard 研究已启动并出具临床报告，实验室已做好运营准备，无需等待其他研究数据即可采取行动扩大可及性。
  • 管理层表示了解相关法律，不会做违法之事。
  • 关于 USPSTF，管理层注意到整个小组可能被替换，但认为在等待指南纳入期间，Shield 当前的健康毛利率和巨大空白市场提供了大量机会。
• Mgmt stance: 中性偏多。对 MCED 机会兴奋，但承认 USPSTF 存在不确定性，同时强调现有业务足以支撑增长。

Q5 — Subhalaxmi T. Nambi

• Topic: Reveal 检测频率趋势及 ADLT 状态更新
• Key points:
  • Reveal 是肿瘤业务中增长最快的产品，新患者启动和后续抽血均有良好进展。
  • 管理层对 Reveal 未来几个季度及 2026 年有高预期，有信心显著提升每患者检测次数。
  • Reveal 的 ADLT 申请已提交，正在等待决定，管理层认为该测试符合 ADLT 资格，预计未来一个季度左右会有结果。
• Mgmt stance: 看多。Reveal 增长加速，且对获得 ADLT 资格持积极态度。

Q&A Batch (6-10 of 10)

Q6 — Kyle Alexander Mikson

• Topic: Reveal Medicare reimbursement timeline & NCCN guideline impact on Shield volumes
• Key points:
  • CRC surveillance Medicare coverage took ~4–5 months (second time), much faster than first.
  • High confidence in Reveal breast submission to MolDX based on prior experience.
  • NCCN inclusion impact on Shield volumes is hard to isolate from overall ramp; remains confident in ACS/USPSTF inclusion.
• Mgmt stance: Bullish — confident in faster Medicare process due to experience; NCCN seen as positive catalyst.

Q7 — Daniel Anthony Arias

• Topic: V2 data timing and program status
• Key points:
  • No exact timing given for V2 data; program is active with ongoing work.
  • Commercial success of V1 allows balancing R&D, including pulling forward MCED clinical validation.
  • Not rushing to V2; focus on lab/operation readiness for patient reporting.
• Mgmt stance: Neutral — no commitment on timing; prioritizing other R&D initiatives.

Q8 — Patrick Bernard Donnelly

• Topic: Profitability path and reinvestment strategy
• Key points:
  • Path to profitability set at 2028 Investor Day; cash burn reducing each year since 2023.
  • Screening burn managed to ~$200M; Q2 gross margins at 48%.
  • Excluding screening, rest of business on track to breakeven before year-end.
• Mgmt stance: Bullish — on track to 2028 breakeven; reinvesting gross profit without increasing overall burn.

Q9 — Rachel Marie Vatnsdal Olson

• Topic: Shield V2 launch timeline and FDA review
• Key points:
  • Launch timeline depends on data readout and FDA review duration; pleased with agency discussions.
  • Year-end launch may be "a little bit delayed"; no rush due to balancing V2 and MCED activities.
  • Extensive work ongoing on V2.
• Mgmt stance: Neutral — acknowledges potential delay; prioritizes R&D balance over speed.

Q10 — Eve Burstein

• Topic: Shield private payer contracting, ADLT rate, and ASP outlook
• Key points:
  • In touch with private payers; not counting on major coverage before ACS/USPSTF guidelines.
  • Confident ADLT rate ($14.95) will remain same through next reporting cycle (Jan '26–Dec '27).
  • ASP depends on payer mix; will set expectations closer to 2026.
• Mgmt stance: Neutral — early in commercial execution; no major coverage expected soon; ASP guidance deferred.

Q&A Batch (11-12 of 12)

Q11 — William Bishop Bonello

• Topic: Guardant360液体活检从组织优先向液体优先的演变对Reveal的启示
• Key points:
  • Infinity平台Smart Liquid Biopsy生态系统中的应用将迁移至360 Tissue和Reveal
  • Reveal可检测亚型、演变及辅助治疗毒性等生物学信息，非仅乘客突变
  • MRD市场分为肿瘤知情与无组织两部分，无组织液体部分预计更大
  • CGP领域液体市场最终将远超组织市场，MRD或呈现相同动态
• Mgmt stance: 看涨，因无组织液体MRD市场规模潜力巨大且与CGP趋势一致

Q12 — Yuko Oku

• Topic: SERENA-6读出后ESR1突变监测在G360全面面板与热点检测间的稳态分配及Medicaid影响
• Key points:
  • ESR1为动态适应性疾病管理新范式首个机会，G360为camizestrant注册检测及美国CDx
  • 预计未来数年G360量能捕获该范式大部分机会与量能
  • Medicaid量能在整体量能中极小，收入端占比更低
  • Medicaid削减对整体量能或收入无实质影响
• Mgmt stance: 看涨，因G360在ESR1监测新范式中具备显著量能上行空间且Medicaid风险可忽略